Literature DB >> 15110498

Osteogenesis imperfecta.

Frank Rauch1, Francis H Glorieux.   

Abstract

Osteogenesis imperfecta is a genetic disorder of increased bone fragility, low bone mass, and other connective-tissue manifestations. The most frequently used classification outlines four clinical types, which we have expanded to seven distinct types. In most patients the disorder is caused by mutations in one of the two genes encoding collagen type 1, but in some individuals no such mutations are detectable. The most important therapeutic advance is the introduction of bisphosphonate treatment for moderate to severe forms of osteogenesis imperfecta. However, at present, the best treatment regimen and the long-term outcomes of bisphosphonate therapy are unknown. Although this treatment does not constitute a cure, it is an adjunct to physiotherapy, rehabilitation, and orthopaedic care. Gene-based therapy presently remains in the early stages of preclinical research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110498     DOI: 10.1016/S0140-6736(04)16051-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  305 in total

1.  Efficacy and safety of 2-year etidronate treatment in a child with generalized arterial calcification of infancy.

Authors:  Thomas Edouard; Gilles Chabot; Joaquim Miro; Daniela Christina Buhas; Yvonne Nitschke; Chantale Lapierre; Frank Rutsch; Nathalie Alos
Journal:  Eur J Pediatr       Date:  2011-09-20       Impact factor: 3.183

Review 2.  Aortic dissection in osteogenesis imperfecta: case report and review of the literature.

Authors:  Michael F McNeeley; Brian N Dontchos; Michael A Laflamme; Michal Hubka; Claudia T Sadro
Journal:  Emerg Radiol       Date:  2012-04-20

3.  Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year.

Authors:  Joanne Ruck; Noémi Dahan-Oliel; Kathleen Montpetit; Frank Rauch; François Fassier
Journal:  J Child Orthop       Date:  2011-05-08       Impact factor: 1.548

Review 4.  Gone Caving: Roles of the Transcriptional Regulators YAP and TAZ in Skeletal Development.

Authors:  Christopher D Kegelman; Joseph M Collins; Madhura P Nijsure; Emily A Eastburn; Joel D Boerckel
Journal:  Curr Osteoporos Rep       Date:  2020-10       Impact factor: 5.096

5.  Single molecule effects of osteogenesis imperfecta mutations in tropocollagen protein domains.

Authors:  Alfonso Gautieri; Simone Vesentini; Alberto Redaelli; Markus J Buehler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

6.  Connective tissue alterations in Fkbp10-/- mice.

Authors:  Caressa D Lietman; Abbhirami Rajagopal; Erica P Homan; Elda Munivez; Ming-Ming Jiang; Terry K Bertin; Yuqing Chen; John Hicks; MaryAnn Weis; David Eyre; Brendan Lee; Deborah Krakow
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

Review 7.  Osteogenesis imperfecta and therapeutics.

Authors:  Roy Morello
Journal:  Matrix Biol       Date:  2018-03-11       Impact factor: 11.583

8.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

Review 9.  Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans.

Authors:  Joan C Marini; Antonella Forlino; Wayne A Cabral; Aileen M Barnes; James D San Antonio; Sarah Milgrom; James C Hyland; Jarmo Körkkö; Darwin J Prockop; Anne De Paepe; Paul Coucke; Sofie Symoens; Francis H Glorieux; Peter J Roughley; Alan M Lund; Kaija Kuurila-Svahn; Heini Hartikka; Daniel H Cohn; Deborah Krakow; Monica Mottes; Ulrike Schwarze; Diana Chen; Kathleen Yang; Christine Kuslich; James Troendle; Raymond Dalgleish; Peter H Byers
Journal:  Hum Mutat       Date:  2007-03       Impact factor: 4.878

10.  CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.

Authors:  Dustin Baldridge; Ulrike Schwarze; Roy Morello; Jennifer Lennington; Terry K Bertin; James M Pace; Melanie G Pepin; Maryann Weis; David R Eyre; Jennifer Walsh; Deborah Lambert; Andrew Green; Haynes Robinson; Melonie Michelson; Gunnar Houge; Carl Lindman; Judith Martin; Jewell Ward; Emmanuelle Lemyre; John J Mitchell; Deborah Krakow; David L Rimoin; Daniel H Cohn; Peter H Byers; Brendan Lee
Journal:  Hum Mutat       Date:  2008-12       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.